Pediatric patients (those aged 0-21 years) account for only 1% of the prevalent population receiving kidney replacement therapy (KRT)1 but are a unique subset differing from adults in both underlying kidney diseases and treatment needs.2 The biggest difference is that children must achieve adult maturation through growth and development from birth through adolescence. During this time, they are dependent on adults for care, nurturing, and supervision. Additionally, common comorbid conditions are not diabetes, heart disease, cerebrovascular disease, gout, and smoking, but seizure disorder, cognitive impairment, behavioral abnormalities, and nonkidney congenital anomalies, including congenital heart disease.